The AKT inhibitor, MK-2206 was able to induce dose-dependent apoptosis of isolated PBMCs (containing > 90% leukemic T-cells) of T-PLL patients (n = 4) (IC50: 5 μM) [15]. This evidence concerns the gene AKT1 and prolymphocytic leukemia.